Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

Caitlin E. Cox

October 16, 2025

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

News Daily News

Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities

Michael O'Riordan

April 25, 2022

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

News Conference News SCAI 2021

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

Michael O'Riordan

May 06, 2021

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

News Daily News

Stable CAD With High-Risk Anatomy Warrants PCI or CABG, APPROACH Suggests

Michael O'Riordan

January 05, 2021

News Conference News ESC Heart Failure 2019

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

Shelley Wood

May 28, 2019

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Daily News

Majority of US Patients Still Discharged on High-Dose Aspirin After Acute MI

Todd Neale

August 20, 2014

News Daily News

Hospital-Level Factors Likely Explain Why Some VA Patients Don’t Get Timely Post-PCI Clopidogrel

Caitlin E. Cox

June 17, 2014

News Daily News

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Jason Kahn

August 05, 2013

News Conference News ACC 2013

STREAM: Fibrinolysis Strategy Effective for STEMI Patients Far From PCI Hospital

Yael L. Maxwell

March 09, 2013

News Daily News

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

February 27, 2013

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Daily News

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

June 05, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

Advertisement

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Stable CAD With High-Risk Anatomy Warrants PCI or CABG, APPROACH Suggests

Steep Rise in PCI for Ischemic Heart Failure Seen in Sweden, but Survival Favors CABG

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

NSAIDs Plus Anticoagulants a Bad Combination

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

Majority of US Patients Still Discharged on High-Dose Aspirin After Acute MI

Hospital-Level Factors Likely Explain Why Some VA Patients Don’t Get Timely Post-PCI Clopidogrel

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

STREAM: Fibrinolysis Strategy Effective for STEMI Patients Far From PCI Hospital

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content